PDLI PDL Biopharma

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.

Company profile

John McLaughlin
Fiscal year end
Former names
IRS number

PDLI stock data



28 Mar 21
2 Aug 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 126.84M 126.84M 126.84M 126.84M 126.84M
Cash burn (monthly) (positive/no burn) 3.51M 4.13M 24.5M 7.37M
Cash used (since last report) n/a 24.93M 29.31M 173.92M 52.34M
Cash remaining n/a 101.91M 97.53M -47.07M 74.5M
Runway (months of cash) n/a 29.0 23.6 -1.9 10.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Feb 21 Silver Point Capital Common Stock Buy Aquire P No No 2.05 187,061 383.48K 23,970,334
30 Dec 20 Gryska David W Common stock Sell Dispose S No No 2.74 20,000 54.8K 1,387
30 Dec 20 Silver Point Capital Common Stock Buy Aquire P No No 2.5 6,325,213 15.81M 23,783,273
29 Dec 20 Silver Point Capital Common Stock Buy Aquire P No No 2.69 268,600 722.53K 17,458,060
28 Dec 20 Silver Point Capital Common Stock Buy Aquire P No No 2.7 235,000 634.5K 17,189,460
24 Dec 20 Silver Point Capital Common Stock Buy Aquire P No No 2.65 128,000 339.2K 16,954,460

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 10 36 -72.2%
Opened positions 0 6 EXIT
Closed positions 26 101 -74.3%
Increased positions 1 6 -83.3%
Reduced positions 0 14 EXIT
13F shares
Current Prev Q Change
Total value 36.74M 138.51M -73.5%
Total shares 14.9M 56.96M -73.8%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest transactions
Shares Bought/sold Change
Silver Point Capital 0 -23.78M EXIT
Dimensional Fund Advisors 0 -7.67M EXIT
Brandes Investment Partners 0 -7.05M EXIT
JBF Capital 0 -543.99K EXIT
Gabelli Funds 0 -512.53K EXIT
Context Capital Management 0 -465.17K EXIT
California Public Employees Retirement System 0 -252.97K EXIT
Russell Investments 0 -196.78K EXIT
HWC Hancock Whitney 0 -187.76K EXIT

Financial report summary

Management Discussion
  • Throughout our history, our mission has been to improve the lives of patients by aiding in the successful development of innovative therapeutics and healthcare technologies. PDL BioPharma was founded in 1986 as Protein Design Labs, Inc. when it pioneered the humanization of monoclonal antibodies, enabling the discovery of a new generation of targeted treatments that have had a profound impact on patients living with different cancers as well as a variety of other debilitating diseases. In 2006, we changed our name to PDL BioPharma, Inc.
  • Historically, we generated a substantial portion of our revenues through the license agreements related to patents covering the humanization of antibodies, which we refer to as the Queen et al. patents. In 2012, and in anticipation of declining revenues from the Queen et al. patents, we began providing alternative sources of capital through royalty monetization and debt facilities, and, in 2016, we began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products, first with our acquisition of branded prescription pharmaceutical drugs from Novartis in 2016 and, in 2017, with the acquisition of LENSAR, a medical device ophthalmology equipment manufacturing company. In 2019, we entered into a securities purchase agreement with Evofem pursuant to which we invested $60.0 million in a private placement of securities. These investments provided funding for Evofem’s pre-commercial activities for Phexxi®, its non-hormonal, on-demand prescription contraceptive gel for women.
Content analysis
H.S. junior Avg
New words: admitted, Adverum, advisor, AEON, AerCap, aerospace, Airco, aircraft, Alan, Alexion, Alpine, Alza, Amgen, Amphastar, Amsterdam, Andersen, Anesiva, arisen, array, Arthur, AxoGen, bad, Bar, Barbara, barred, Bay, Bazaar, Beautiful, benchmark, benchmarking, Bidco, Biochemistry, BioDelivery, biographical, block, Boise, borne, bought, Brevard, Brook, Bucknell, buyer, CA, career, Cascade, CAT, Catholic, CEO, Chairman, chairperson, chairpersonship, checklist, Chem, Christopher, clawback, client, COBRA, cognizant, Collegium, color, Columbia, column, compel, compliant, concession, conclusion, conferred, conflict, contrast, Convenience, Corcept, Corgentech, couple, culminating, customarily, Dame, Danisco, de, deceased, declassification, defense, delegate, delegated, dental, depicted, deregistration, devised, DGCL, diligence, disability, disbanded, disbanding, discourage, discouraged, disqualified, disqualifying, disregard, distinguished, Dominique, double, drew, Eagle, Eastern, EDHEC, Edward, elapsed, Elizabeth, employed, Enbrel, ENT, equating, equitable, Ernst, exhaustive, expedient, Eyetech, fashion, FL, Fontainebleau, footnote, Forest, forfeit, forfeited, foundation, France, Francisco, freely, FTB, Genencor, George, Geron, Gryska, Halozyme, hamper, hardship, head, headcount, Hernday, highlight, Hollow, House, housing, Hudson, Imbrogno, Immune, incentivize, incentivizing, inconsistent, incorrect, Indiana, Inflammation, Inhibikase, ink, Innoviva, INSEAD, Intersect, intestate, Ironwood, Jene, Jill, John, Latin, Ligand, Lille, linking, listen, LNSR, LoJack, longstanding, LTIP, matching, McLaughlin, Media, median, Medtronic, membership, microbiology, mind, Monnet, multinational, multiplied, NaN, Natasha, nephrology, NOL, noncash, Notre, NTS, official, oncology, ophthalmology, opt, OSI, OTC, oversaw, overview, overwhelming, Pacira, pandemic, payout, Peak, peer, Pennsylvania, Pepperdine, percentile, permissible, Phexxi, philosophy, poll, preexisting, printer, Procurement, proximate, Radford, ratified, ratio, ready, recoupment, recuse, referenced, relocate, Reno, Republic, resold, resource, Respectfully, Retrophin, Richard, robust, Rockwell, salary, salesforce, San, Sandman, Santa, School, scoring, Scott, Seagen, Seattle, Secretary, seller, shown, signal, skill, Sparton, specialist, Spectrum, Stanley, Stern, Stone, stood, strongly, superseded, survey, SWK, talent, telephone, Teligent, terrorist, text, therewith, thousand, tied, Township, Tularik, uncontested, undergraduate, underperformance, underwater, unexercisable, unjustly, unmatured, unregistered, unresolved, unsatisfactory, unsettled, valuable, Vanda, VAT, vice, view, vision, Wake, Wall, Waterhouse, Wealth, weather, Whipple, withdrawn, withhold, wrongful, Xoma, Yanai, YMCA, Young, Zug
Removed: abandon, abroad, absent, absorption, abuse, ACA, acceptable, accepting, accomplished, Accountability, accurate, acquiree, adapt, add, adding, Additionally, adherence, administered, adulteration, advertise, advertising, affiliated, affix, affixed, Affordable, agency, alpha, altered, ambulatory, Amerisource, analytical, anatomical, animal, anterior, API, applicant, approvability, arcuate, ARIAD, arranging, ascertained, assembly, assert, attain, attempt, attempting, attention, attorney, Augmented, automated, automatic, automation, avoid, bankruptcy, bear, bearing, Bergen, beta, bill, biologic, body, brand, breadth, breakthrough, breast, bribe, bribery, bring, broad, broader, broadly, bulk, bundle, bundling, buying, calcium, canceled, cancellation, cancer, candidate, capable, capsulotomy, Cardinal, cardioselective, catastrophic, CE, central, centrally, certify, cGMP, chain, challenge, challenged, Chapter, Charter, chemistry, children, chin, chronic, chronological, claiming, clarification, classify, clearance, cleared, clinically, CMS, combining, community, comparability, comparative, compendia, competing, complicate, complicating, complication, comprising, compromised, compulsory, concealing, concurrently, Conformit, considerable, consolidate, constrain, consume, consummated, Contemporaneously, context, continuity, convened, convening, coordination, Corrupt, Cosmetic, costly, counterfeit, covertly, created, critically, curtailment, custom, customization, cycle, cyclorotation, daily, dated, death, deceive, decide, declaration, decree, defaulted, defending, deficiency, defraud, deliberate, demonstrate, demonstrated, demonstrating, denominated, deny, deoxycholic, Department, deposited, deprive, desirable, desired, detailing, detect, detected, detection, detention, deteriorate, deterioration, devote, diet, digit, diminish, dipeptidyl, Directive, disagree, disagreement, discontinue, disgorgement, disincentive, dispenser, dispersed, disruption, disruptive, dissatisfaction, dissemination, diversion, divert, divesting, doctor, Dohme, dominate, dose, dosing, dossier, dramatically, drawn, Dublin, earliest, ease, EEA, elaborate, electronic, embezzling, emerged, Empagliflozin, endpoint, enforceability, enforced, enrolled, ensuring, entitle, entrance, enumerated, equivalence, erosion, establishment, estimable, euro, Europe, eventually, evolving, exacerbated, exclusion, excretion, executing, exempt, exemptive, exhibit, exist, expand, expanded, expanding, expansion, expedite, expend, expensive, export, expose, exposed, expropriation, facility, factual, failed, failing, false, falsifying, fast, fat, FCPA, FDASIA, federally, FERA, fewer, FFDCA, field, fill, fine, Florida, fluctuate, forced, forego, formula, formulary, fragmentation, fraudulent, fs, fulfill, furnish, gather, GCP, geographically, geopolitical, GILTI, globally, GLP, goodwill, governing, greatest, greatly, grow, growing, guide, guided, harm, harmed, healthy, heightened, highest, HIPAA, HITECH, hospital, host, Iclusig, IDE, identity, illegal, illiquidity, immigration, impacting, implantable, implanted, implement, implemented, imply, import, impose, imposition, imprisonment, improper, improperly, improvement, improving, incident, incoming, incorporating, increasingly, incurring, IND, indemnification, induce, inflation, infringed, infused, inhaled, inhibit, initiative, injectable, injected, innovation, innovator, inquiry, insignificant, inspect, inspection, Inspectional, inspector, instance, instilled, instituting, institution, institutional, insufficient, integrate, integration, integrity, intense, intentional, Interlaminar, intermittently, interpretation, interpreted, interrupt, invalidated, invasive, investing, investor, IRB, Irish, irrespective, irreversible, irrevocable, jeopardize, Jersey, jurisdiction, Keytruda, kickback, knowingly, labeling, labor, laboratory, language, legality, legally, legislation, legislative, lengthier, lengthy, leukemia, leverage, limiting, Linagliptin, liquidated, literature, lose, lumbar, macroeconomic, majeure, malfunction, malfunctioned, mandate, manually, mark, marked, marking, matured, McKesson, MCO, medication, metabolism, minimization, misconduct, misleading, misused, mitigate, mitigation, mixture, mode, moderate, modernize, modifying, molecular, molecule, monetary, monitor, morbidity, mortality, myeloid, narrowly, NDA, necessitate, necessity, newly, NIH, noncompliance, noncontrolling, object, objective, observed, obstructing, occupy, offense, ophthalmic, opioid, optional, ordering, organization, originally, Orlando, outlay, outlining, outpatient, outweigh, overlap, overtly, packaged, packaging, panel, paragraph, Passive, PDUFA, pediatric, penalty, penetration, perception, periodic, permitting, pertain, pervasive, PhRMA, physical, physician, pilot, plaintiff, PMA, ponatinib, Portability, pose, posed, positive, PREA, precautionary, precedent, preclinical, predicate, predicted, predominantly, preliminarily, preliminary, premarket, Presafe, prescribing, prevalence, prevented, preventing, priority, privacy, processed, produce, produced, production, profile, profitability, profitably, prohibiting, prohibition, prolong, promising, promoting, promotional, promulgated, proof, proportion, propose, prosecute, prosecuted, prosecuting, prosecution, protected, protecting, protocol, provisional, publicity, published, purity, pursued, put, QSR, qualifying, questioning, qui, rapid, rarity, realizing, reauthorized, recent, recommending, reconsider, recordkeeping, recuperate, recur, reevaluation, referral, refinance, refusal, register, regular, regulate, regulated, reimbursable, reimbursed, reinvesting, reliability, reliance, reluctant, remedy, remuneration, rendering, renewed, reorganization, reorganized, repeal, repeated, replace, repurchasing, reputation, reputational, responding, response, restrict, restrictive, resubmitted, revaluation, reveal, revision, rolling, routine, Royal, rulemaking, safer, sampling, satisfactory, scale, scheme, scientific, scientifically, scope, scrutiny, SDK, se, secondary, secure, seizure, sequential, servicing, setting, shape, Sharing, Sharp, shipped, shortened, shutdown, significance, Similarly, simple, simplify, sizeable, skeletally, sound, Southwood, spending, sponsor, spun, Stabilization, stage, statistical, statistically, stealing, storage, strain, stream, Streamline, strength, studied, subleased, submental, Subpart, subpopulation, substandard, substantiate, substantive, succeed, successfully, sued, suffer, sufficiently, sunshine, supervision, supplement, supplier, supported, surrogate, surveillance, sustain, Takeda, tam, taxed, teaching, technique, technological, territory, Teva, theft, therefrom, thereto, thiazide, thought, thoughtful, tier, timeframe, tolerance, Toric, toxicity, tracing, tracking, transmission, transparency, treat, treating, treaty, treble, trebling, trend, trending, Trump, truthful, unacceptable, unannounced, unauthorized, unclear, unconsolidated, uncooperative, understand, undertaken, undesirable, unexpected, unfair, uninterrupted, unpredictability, unrest, unscheduled, unsecured, unstable, unsuccessful, unsupported, untitled, validity, variation, varying, vendor, verification, verify, violate, violation, warning, weakened, weekly, whistleblower, wholesale, willfully, write


Low Crossing Profile Delivery Catheter for Cardiovascular Prosthetic Implant
9 Sep 20
A delivery catheter and a method for deploying a cardiovascular prosthetic implant using a minimally invasive procedure are disclosed.
Filtration module
20 Jul 20
Provided is a filtration module for separating plasma from blood comprising a feeder channel lid, a feeder channel defined by a feeder channel laminating layer having a thickness of less than 5 mil, a filter element in fluid communication with the feeder channel and having a pore size of less than 2 microns and low surface area, and a filtrate take-off port having a dead volume of less than 10 μL.
Antibodies and Methods for the Detection of Cell Death
5 Feb 20
Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK18 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unbound or excess material; and detecting the signal from the detection moiety, wherein the signal is positively correlated with the presence of the CK18 protein fragment in the sample.